Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epinephrine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Epinephrine | EXPERIMENTAL | Dosage Level: Part 1 of the study: Participants across cohort 1 to 3 will receive a single dose of either 1mg or 1.3mg or 1.5mg respectively of epinephrine or placebo via DMC-IHI device. Dosage form: Single-use capsule based dry powder inhaler Route of administration: Inhalation |
| Placebo | PLACEBO_COMPARATOR | Drug: Placebo Participants will receive matching placebo across the study. |
| Name | Type | Description |
|---|---|---|
| Epinephrine | DRUG | Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device. |
| Placebo | DRUG | Participant in Part 1 of the study will receive matching doses of placebo |
Inclusion Criteria: 1. Is willing to sign an ICF on a voluntary basis and to voluntarily participate in the study, after being able to read the ICF and understand the information contained within, prior to any Screening procedure being undertaken. 2. Male or female and ≥18 to ≤45 years of age at ti...
Epinephrine is used for the treatment of anaphylactic reaction, a severe and potentially life-threatening allergic response. It is being studied as a small molecule therapeutic in the immunology therapeutic area. The drug is currently in Phase 1 clinical development.
Epinephrine is being developed by Cardinal Health, Inc., a company traded on the New York Stock Exchange under the ticker symbol CAH. The company is conducting clinical research on this drug for the treatment of anaphylactic reaction.
Epinephrine is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied for its safety and tolerability in healthy volunteers.
Epinephrine has one completed clinical trial, identified as NCT06013150. This was a Phase 1 study titled "Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants." The trial enrolled 24 participants in Australia.
Epinephrine is the active ingredient in EpiPen, an auto-injector device. The clinical trial NCT06013150 compared an inhaled formulation of epinephrine (DMC-IH1) with intramuscular EpiPen. The study was conducted in healthy volunteers to evaluate the investigational inhaled version.